Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype (PERSEPHONE)
A Phase 2b/Phase 3, Randomized, Double-blind, Placebocontrolled, Multicenter Study, to Investigate the Efficacy and Safety of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Sponsor: Sanofi
A observational or N/A phase clinical study on Chronic Obstructive Pulmonary Disease, this trial is actively recruiting participants. The trial is conducted by Sanofi and has accumulated 7 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Study Description(click to expand)All eligible participants will undergo subcutaneous administrations of lunsekimig or matching placebo during a 48-weeks treatment period
All eligible participants will undergo subcutaneous administrations of lunsekimig or matching placebo during a 48-weeks treatment period
Status Flow
Change History
7 versions recorded-
Apr 21, 2026 — Present [daily]
Recruiting
Phase: PHASE3 → None
-
Mar 2026 — Apr 2026 [monthly]
Recruiting PHASE3
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE3
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE3
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE3
▶ Show 2 earlier versions
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Oct 2025 — Nov 2025 [monthly]
Not Yet Recruiting PHASE3
First recorded
Sep 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. Participation to the study consists of 3 periods: * Screening period of up to 4 weeks * Randomized intervention period of approximately 48 weeks * Follow-up period: Approximately 8 weeks The study duration will be up to 60 weeks.
Contact Information
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .